Biogen (BIIB) Income towards Parent Company (2009 - 2026)
Biogen (BIIB) posted quarterly Income towards Parent Company of $319.5 million for Q1 2026, up 32.85% year-over-year from $240.5 million in Q1 2025, and up 753.37% on a QoQ basis from -$48.9 million in Q4 2025.
Biogen (BIIB) Income towards Parent Company (2009 - 2026) Analysis & Trends
Biogen (BIIB) has reported Income towards Parent Company for 18 consecutive years, with $319.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Income towards Parent Company rose 32.85% year-over-year to $319.5 million; the TTM figure through Mar 2026 stood at $1.4 billion (down 7.26% YoY), while the FY2025 annual figure was $1.3 billion, down 20.79% from the prior year.
- Income towards Parent Company came in at $319.5 million for Q1 2026 at Biogen, up from -$48.9 million in the prior quarter.
- The five-year high for Income towards Parent Company was $1.1 billion in Q3 2022, with the low at -$64.2 million in Q3 2023.
- Average Income towards Parent Company over 5 years is $437.3 million, with a median of $393.4 million recorded in 2024.
- Across the five-year window, Income towards Parent Company surged 948.37% in 2022 and plunged 118.34% in 2025, its largest moves.
- Year by year, Income towards Parent Company stood at $559.0 million in 2022, then sank by 55.47% to $248.9 million in 2023, then increased by 7.15% to $266.7 million in 2024, then slumped by 118.34% to -$48.9 million in 2025, then surged by 753.37% to $319.5 million in 2026.
- According to Business Quant data, Income towards Parent Company over the past three periods registered $319.5 million, -$48.9 million, and $466.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 319.50 Mn |
| Dec 31, 2025 | -48.90 Mn |
| Sep 30, 2025 | 466.50 Mn |
| Jun 30, 2025 | 634.80 Mn |
| Mar 31, 2025 | 240.50 Mn |
| Dec 31, 2024 | 266.70 Mn |
| Sep 30, 2024 | 388.50 Mn |
| Jun 30, 2024 | 583.60 Mn |
| Mar 31, 2024 | 393.40 Mn |
| Dec 31, 2023 | 248.90 Mn |
| Sep 30, 2023 | -64.20 Mn |
| Jun 30, 2023 | 599.70 Mn |
| Mar 31, 2023 | 397.20 Mn |
| Dec 31, 2022 | 559.00 Mn |
| Sep 30, 2022 | 1.14 Bn |
| Jun 30, 2022 | 1.06 Bn |
| Mar 31, 2022 | 243.40 Mn |
| Dec 31, 2021 | -101.70 Mn |
| Sep 30, 2021 | -134.80 Mn |
| Jun 30, 2021 | 528.30 Mn |